

September 24, 2012



# Boston Therapeutics Announces Filing of S-1 Registration Statement

MANCHESTER, NH -- (MARKETWIRE) -- 09/24/12 -- Boston Therapeutics, Inc. (OTCQB: BTHE) ("Boston Therapeutics" or "the Company"), a developer of complex carbohydrate therapeutics to treat diabetes and inflammatory diseases, today announced it has filed an S-1 registration statement with the Securities and Exchange Commission relating to a proposed offering of up to 20 million new shares of its common stock and up to 10 million warrants to purchase additional shares of common stock. The price for the shares of common stock to be offered is \$0.50. For every two shares of common stock, the Company will issue a warrant to purchase one share of common stock with an exercise price of \$1.00 with a five-year term.

The Company plans to use the proceeds from this offering to fund its research and development activities, for working capital and other general corporate purposes.

The offering will be made only by means of a prospectus supplement and accompanying prospectus filed with the Securities and Exchange Commission (SEC). A copy of the preliminary prospectus relating to the offering is available, for free, on the SEC's website at <http://sec.gov>. A copy also may be obtained from the Company. A registration statement relating to these securities has been filed with the Securities and Exchange Commission, but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any offer or sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction.

## ***About Boston Therapeutics, Inc.***

Boston Therapeutics, headquartered in Manchester, NH, (OTCQB: BTHE) is a leader in the field of complex carbohydrates. The Company's initial product pipeline is focused on developing and commercializing therapeutic molecules for diabetes: SUGARDOWN®, a non-systemic chewable complex carbohydrate dietary supplement tablet designed to moderate post-meal blood glucose; PAZ320, a non-systemic chewable therapeutic compound designed to reduce post-meal glucose elevation, and IPOXYN™, an injectable anti-hypoxia drug specifically designed to treat lower limb ischemia associated with diabetes. More information is available at [www.bostonti.com](http://www.bostonti.com).

## ***Forward-Looking Statements***

The Company's views as of the date of this press release should not be relied upon to represent the Company's views as of a subsequent date. While the Company anticipates that subsequent events may cause the Company's views to change, the Company disclaims any obligation to update such forward-looking statements.

More information about those risks and uncertainties is contained and discussed in the Company's most recent quarterly or annual report and in the Company's other reports filed with the Securities and Exchange Commission. The forward-looking statements represent the Company's views as of the date of this press release and should not be relied upon to represent the Company's views as of a subsequent date. While the Company anticipates that subsequent events may cause the Company's views to change, the Company disclaims any obligation to update such forward-looking statements.

**Contact:**

Boston Therapeutics, Inc.  
Anthony Squeglia  
Phone: 603-935-9799  
Email [anthony.squeglia@bostonti.com](mailto:anthony.squeglia@bostonti.com)  
[www.bostonti.com](http://www.bostonti.com)

Investor Relations:  
MZ Group  
Scott Powell  
Senior Vice President  
Phone: 212-301-7130  
Email: [scott.powell@mzgroup.us](mailto:scott.powell@mzgroup.us)  
Web: [www.mz-ir.com](http://www.mz-ir.com)